Results 151 to 160 of about 177,264 (261)

The Efficacy of Transitioning Patients With Pulmonary Hypertension From Phosphodiesterase Type 5 Inhibitors To Riociguat: A Systematic Analysis And Retrospective Chart-Review [PDF]

, 2021
Kelly Sun, Tetyana Kendzerska, Julia Foxhall, Lisa Mielnizuk, Vladimir Contreras-Domínguez, Duncan J. Stewart, C. Pugliese, George Chandy   +7 more
openalex   +1 more source

The safety and efficacy of phosphodiesterase type 5 inhibitors in the treatment of diabetic erectile dysfunction: a systematic review and meta-analysis. [PDF]

PeerJ
Zhu Z, Xu J, Dai B, Lin M, Yang H, Liu S, Bao P, Nan Z.   +7 more
europepmc   +1 more source

Short-term outcomes of phosphodiesterase type 5 inhibitors for fetal growth restriction: a study protocol for a systematic review with individual participant data meta-analysis, aggregate meta-analysis, and trial sequential analysis. [PDF]

Syst Rev, 2021
Liauw J, Groom K, Ganzevoort W, Gluud C, McKinlay CJD, Sharp A, Mackay L, Kariya C, Lim K, von Dadelszen P, Limpens J, Jakobsen JC, STRIDER Consortium.   +12 more
europepmc   +1 more source

Cost comparison of phosphodiesterase type 5 inhibitors: rural vs urban New York State counties and online pharmacies. [PDF]

Sex Med
Di Scipio SM, Katz A.
europepmc   +1 more source

Phosphodiesterase type 5 inhibitors combined with traditional Chinese medicine for diabetes mellitus-induced erectile dysfunction: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Xiang L, Liu A, Tang W, Sun B, Yang Y, Li Y, Chen S, Zhao J, Zhang W, Cai X, Tang X.   +10 more
europepmc   +1 more source

Treatments for erectile dysfunction in spinal cord lesioned patients. Are there alternatives to phosphodiesterase type 5 inhibitors? [PDF]

, 2015
Jean‐Jacques Wyndaele
openalex   +1 more source

Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men [PDF]

, 2014
Jinhong Li, Qingquan Shi, Chunxiao Pu, Yin Tang, Yunjin Bai, Haichao Yuan, Xiang Li, Qiang Dong, Qiang Wei, Jiuhong Yuan, Ping Han   +10 more
openalex   +1 more source

Utilization Trends of Phosphodiesterase Type-5 Inhibitors for Erectile Dysfunction Between 2019 and 2023 in Tanzania. [PDF]

Cureus
Sangeda RZ, Kadinde AW, Masatu CF, Mwalwisi YH, Yahya-Malima KI, Fimbo AM.   +5 more
europepmc   +1 more source

Evaluating of the phosphodiesterase inhibitor type 5 effectiveness in treatment of neurogenic erectile dysfunction in patients with DM type 1

, 2015
Д Г Курбатов, G. R. Galstyan, Yu. G. Shvarts, Р. В. Роживанов, S. A. Dubskiy, А. Е. Лепетухин   +5 more
openalex   +2 more sources

First‐generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta‐analysis

Andrology, 2016
G. Corona, G. Rastrelli, A. Burri, A. Burri, E. Serra, D. Gianfrilli, E. Mannucci, E. Jannini, M. Maggi   +8 more
semanticscholar   +1 more source